Biopharma

Companies

U-PACT is a spin-off molecular diagnostics company of the University Medical Center Utrecht in the Netherlands, with decades of experience in blood platelet biology and diagnostics of bleeding disorders. U-PACT develop technology to provide comprehensive tools for accurate assessment of bleeding risk.

Broteio Pharma

Cavadis is a biomedical company, established as a joint initiative by leading scientists at the department of Experimental Cardiology of the University Medical Centre of Utrecht and the department of Bioinformatics of the Erasmus MC Rotterdam. Cavadis delivers diagnostic and therapeutic tools for the treatment of patients who are prone to develop unstable cardiovascular syndromes due to the presence of multiple thrombogenic vulnerable plaques.

Cristal Therapeutics develops a proprietary product portfolio based on innovative combinations of its technology with new as well as marketed drugs. Its nanoparticulate drug delivery platform increases efficacy, safety and convenience of pharmaceutical products through tuneable and controlled drug release inside the body. Cristal Therapeutics is a spin-off company of the Department of Pharmaceutics of Utrecht University,

Spin-off that focuses on the development, diagnostics and therapeutics for protein accumulation diseases. Crossbeta Biosciences has broad intellectual property coverage of screening tools and for therapeutics in its areas of focus.

EnCare Biotech is privately owned biopharmaceutical company, which was founded in 2014 as a spin off from the University Medical Center Utrecht in The Netherlands. The company’s lead product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin.

Phytogenix performs contract research for other companies by performing bioassays for the bio typing of biologically active compounds. Furthermore it focuses on the discovery of biologically active (plant-derived) lead compounds for further development into (phytogenic) drugs.

PIFA Therapeutics

This company focuses on the development of novel medicines for the treatment and prevention of inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease. It is a spin-off company of the Faculty of Veterinary Medicine of Utrecht University.

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM®, an intranasal vaccine to prevent respiratory syncytial virus infection. Their vaccines are based on the patented and validated Mimopath® technology. This technology enables a more natural immune response as well as a broad base of protection. Mucosis has an extensive R&D collaboration with Utrecht University for the development of an vaccine for RSV.

Prothix is biotech company dedicated to the development of recombinant therapeutic proteins that address the medical need of patients with inflammatory and coagulation disorders. The company utilizes a so-called niche-buster strategy to capitalize its product portfolio.

Simibio

Simibio BV is an early stage company active in the development of therapeutic monoclonal antibodies. Antibodies are an important part of the body’s natural defense system and are normally produced by our immune system to help our bodies fight diseases such as cancer. Monoclonal antibodies are the dominant class of therapeutically important antibodies.

The company conducts fundamental and applied research in the field of cytokine biology. U-Cytech develops, manufactures and sells a wide range of innovative cytokine ELISA and ELISPOT systems for human, monkey and rodent use.

Gadeta B.V. is a Research & Development company established in 2015, which focusses on the development of innovative immunotherapies for cancer. The work of the company is based on the groundbreaking discoveries regarding the role of γδ T cell receptors (TCR’s) in the broad recognition of heamatological and solid tumour cells and their potential use for the treatment of advanced malignancies as discovered by Prof. Dr. Jürgen Kuball at the University Medical Centre Utrecht (UMCU), The Netherlands.